Budesonide 15 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
Budesonide 9 mg probably leads to lower induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with conventional steroids (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
It is very uncertain whether budesonide 9 mg changes withdrawal due to disease worsening compared with conventional steroids (very low certainty).
Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeksThomsen 1998 compared with mesalamine (moderate certainty).
Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 9 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI < 150) compared with mesalamine (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).
Budesonide 9 mg probably leads to lower withdrawal due to disease worsening compared with mesalamine (moderate certainty).
Budesonide 3 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (moderate certainty).
Budesonide 3 mg showed no clear difference in corticosteroid related adverse events compared with placebo (low certainty).
Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
Budesonide 9 mg probably leads to higher clinical improvement (decrease in CDAI > 100 or total CDAI < 150) ‐… compared with placebo (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (low certainty).
Budesonide 9 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).
Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).
Budesonide MMX® 6 mg showed no clear difference in histologic remission compared with placebo (low certainty).
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).